Skip to main content

Table 1 Clinical characteristics of patients with prolonged meropenem therapy (MT) > 4 weeks and controls (ICU-stay > 4 weeks and meropenem therapy ≤ 14 days)

From: Risk factors for excessively prolonged meropenem use in the intensive care setting: a case-control study

  Casesa Controlsb p
Number of patients 36 108  
Duration of uninterrupted meropenem use, days, median (IQR) 34 (31–39) 9 (7–11) <0.001
Age in years, median (IQR) 63 (51–71) 66 (56–73) 0.26
Female sex, n (%) 13 (36.1) 36 (33.3) 0.76
Days on ICU, median (IQR) 66 (51.5–92.5) 35 (31–45) <0.001
Malignancy, n (% of all pts) 17 (47.2) 22 (20.4) 0.002
SAPS score at admission, median (IQR) 42 (35–48) 39 (33–47) 0.36
Medical patients, n (% of all pts) 4 (11.1) 45 (42.7) 0.001
Neurological patients, n (% of all pts) 6 (16.7) 30 (26.9) 0.22
Surgical patients, n (% of all pts) 26 (72.2) 34 (31.5) <0.001
Number of operations, median (IQR)c 14 (5–27) 4 (3–7) <0.001
Colonization/infection with carbapenem-susceptible, multidrug-resistant Enterobacteriaceae n (%) 7 (19.4) 7 (6.5) 0.007
Type of infection, n (%)
 pneumonia 4 (11.1) 27 (25.0) <0.001
 peritonitis 16 (44.4) 5 (4.6)
 mediastinitis 6 (16.7) 4 (3.7)
 unclear focus 10 (27.8) 72 (66.7)
In-ICU-mortality, n (%) 16 (44.4%) 27 (25.0%) 0.03
  1. apatients with ICU stay > 4 weeks and MT > 28 days
  2. bpatients with ICU stay > 4 weeks and MT ≤ 14 days
  3. cin surgical patients
  4. Abbreviations: IQR: interquartile range SAPS: simplified acute physiology score MT: meropenem therapy